TY - JOUR
T1 - Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey
AU - Sardanelli, Francesco
AU - Aase, Hildegunn S.
AU - Álvarez, Marina
AU - Azavedo, Edward
AU - Baarslag, Henk J.
AU - Balleyguier, Corinne
AU - Baltzer, Pascal A.
AU - Beslagic, Vanesa
AU - Bick, Ulrich
AU - Bogdanovic-Stojanovic, Dragana
AU - Briediene, Ruta
AU - Brkljacic, Boris
AU - Camps Herrero, Julia
AU - Colin, Catherine
AU - Cornford, Eleanor
AU - Danes, Jan
AU - de Geer, Gérard
AU - Esen, Gul
AU - Evans, Andrew
AU - Fuchsjaeger, Michael H.
AU - Gilbert, Fiona J.
AU - Graf, Oswald
AU - Hargaden, Gormlaith
AU - Helbich, Thomas H.
AU - Heywang-Köbrunner, Sylvia H.
AU - Ivanov, Valentin
AU - Jónsson, Ásbjörn
AU - Kuhl, Christiane K.
AU - Lisencu, Eugenia C
AU - Luczynska, Elzbieta
AU - Mann, Ritse M.
AU - Marques, Jose C.
AU - Martincich, Laura
AU - Mortier, Margarete
AU - Müller-Schimpfle, Markus
AU - Ormandi, Katalin
AU - Panizza, Pietro
AU - Pediconi, Federica
AU - Pijnappel, Ruud M.
AU - Pinker, Katja
AU - Rissanen, Tarja
AU - Rotaru, Natalia
AU - Saguatti, Gianni
AU - Sella, Tamar
AU - Slobodníková, Jana
AU - Talk, Maret
AU - Taourel, Patrice
AU - Trimboli, Rubina M.
AU - Vejborg, Ilse
AU - Vourtsis, Athina
AU - Forrai, Gabor
PY - 2017/7
Y1 - 2017/7
N2 - EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50-69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1-10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40-49 years and 70-74 years, although with "limited evidence". Thus, we firstly recommend biennial screening mammography for average-risk women aged 50-69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40-45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become "routine mammography" in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged.KEY POINTS: • EUSOBI and 30 national breast radiology bodies support screening mammography. • A first priority is double-reading biennial mammography for women aged 50-69 years. • Extension to 73-75 and from 40-45 to 49 years is also encouraged. • Digital mammography (not film-screen or computer radiography) should be used. • DBT is set to become "routine mammography" in the screening setting in the next future.
AB - EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50-69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1-10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40-49 years and 70-74 years, although with "limited evidence". Thus, we firstly recommend biennial screening mammography for average-risk women aged 50-69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40-45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become "routine mammography" in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged.KEY POINTS: • EUSOBI and 30 national breast radiology bodies support screening mammography. • A first priority is double-reading biennial mammography for women aged 50-69 years. • Extension to 73-75 and from 40-45 to 49 years is also encouraged. • Digital mammography (not film-screen or computer radiography) should be used. • DBT is set to become "routine mammography" in the screening setting in the next future.
KW - Breast cancer
KW - Population-based screening
KW - Digital mammography
KW - Digital breast tomosynthesis (DBT)
KW - Recall rate
U2 - 10.1007/s00330-016-4612-z
DO - 10.1007/s00330-016-4612-z
M3 - Article
C2 - 27807699
SN - 0938-7994
VL - 27
SP - 2737
EP - 2743
JO - European Radiology
JF - European Radiology
IS - 7
ER -
